7 March 2024 in Arthritis & Rheumatology
TGthe Japan CAPS Working Group
the Japan CAPS Working Group
+80
9 December 2022 in Clinical Immunology
1 January 2025 in Case Reports in Pediatrics
Benzodiazepines are one of the commonly used prescription anxiolytic drugs; however, they are increasingly used for drug abuse, drug crime, and sometimes for medical child abuse. To prevent misuse of high‐potency benzodiazepines, some of them are currently manufactured as a tablet with a speckled blue core that dyes liquid blue when dissolved in drinks. Diagnosing drug poisoning, especially in cases of medical child abuse, can be challenging when signs of ingesting drugs, including empty medical packages, are missing. Herein, we report an infant’s case of benzodiazepine poisoning, who was diagnosed with disturbed consciousness and a blue‐colored tongue. An 11‐month‐old boy was referred to our hospital as his tongue was colored blue. According to his family, no blue‐colored items were found around him when they noticed his tongue was blue. Physical examination revealed his consciousness was slightly disturbed. Benzodiazepine poisoning was suspected from his level of consciousness and blue‐colored tongue, and it was detected using a urine drug test kit (SIGNIFY ER). Medical child abuse was suspected, as accidental ingestion was not likely to happen in the circumstances heard from his family members. Everyone around him denied having benzodiazepine, and how he ingested the medicine was not revealed despite intensive investigation by the police. Benzodiazepine poisoning should be considered in patients presenting with a blue tongue with disturbed consciousness. Adding dyes to medicines commonly used for poisoning may be helpful in recognizing and preventing child abuse.
8 March 2022 in Research Square
PurposeUpregulation of type I interferon (IFN) signaling has been increasingly detected in inflammatory diseases. Recently, upregulated IFN signature has been suggested as a potential biomarker to identify IFN-driven inflammatory diseases. Yet, it remains unclear to what extent type Ⅰ IFN is involved in the pathogenesis of undifferentiated inflammatory diseases. This study aimed to quantify the type Ⅰ IFN signature in clinically undiagnosed patients and assess clinical characteristics in those with a high IFN signature. Methods A type Ⅰ IFN signature was measured in patients’ whole blood cells. Clinical and biological data were collected retrospectively, and an intensive genetic analysis was performed in undiagnosed patients with a high IFN signature.ResultsA total of 113 samples from 94 patients with inflammatory diseases, including 37 undiagnosed cases, were analyzed. Increased IFN signaling was observed in 19 undiagnosed patients, with ten exhibiting clinical features commonly found in type Ⅰ interferonopathies. Skin manifestations, observed in eight patients, were macroscopically and histologically similar to those found in proteasome-associated autoinflammatory syndrome. Genetic analysis identified novel mutations in the PSMB8 gene of one patient, and rare variants of unknown significance, in genes linked to type Ⅰ IFN signaling, in four patients. A JAK inhibitor effectively treated the patient with the PSMB8 mutations. Patients with clinically quiescent idiopathic pulmonary hemosiderosis and A20 haploinsufficiency showed enhanced IFN signaling.ConclusionsHalf of the patients examined in this study, with undifferentiated inflammatory diseases, clinically quiescent A20 haploinsufficiency, or idiopathic pulmonary hemosiderosis, had an elevated type Ⅰ IFN signature.